Immunology and Cancer Immunotherapy (ICI)

免疫学和癌症免疫治疗 (ICI)

• 批准号: 10311236
• 负责人: Mary Jo Turk
• 金额: $ 6.13万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-04 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10311236
• 关键词: Address; Advanced Development; Advocate; Antitumor Response; Applications Grants; Area; Award; CAR T cell therapy; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Patient; Cellular biology; Clinical; Clinical Research; Clinical Trials; Collaborations; Development; Direct Costs; Engineering; Ensure; Equipment; Faculty; Fostering; Funding; Future; Goals; Grant; Health; Health system; Human; Image; Immune; Immune checkpoint inhibitor; Immune system; Immunologics; Immunologist; Immunology; Immunotherapeutic agent; Immunotherapy; Institution; Intervention; Journals; Laboratories; Laboratory Finding; Leadership; Ligands; Malignant Neoplasms; Mentors; Mentorship; Mission; Modality; Molecular; Mosaicism; Patients; Peer Review; Population Sciences; Publications; Radiobiology; Research; Research Personnel; Research Support; Resources; Schools; Scientist; Sum; T memory cell; T-Lymphocyte; Therapeutic; Training; Translating; Translational Research; United States National Institutes of Health; Work; Writing; bench to bedside; cancer immunotherapy; cancer therapy; career; chimeric antigen receptor T cells; drug efficacy; engineered T cells; immune checkpoint blockade; immunoregulation; immunotherapy clinical trials; improved; innovation; interest; medical schools; meetings; member; novel; pre-clinical; programs; recruit; standard of care; success; tumor immunology; tumor microenvironment; viral nanoparticle; working group

Project Summary/Abstract: Immunology and Cancer Immunotherapy The Immunology and Cancer Immunotherapy (ICI) Program brings together 21 faculty, representing seven departments at Dartmouth’s Geisel School of Medicine (Geisel), its Thayer School of Engineering, and the Dartmouth-Hitchcock Health system (D-H), with research interests relevant to three central ICI Program themes: 1) Immune regulation and checkpoint blockade, 2) Tumor microenvironment, and 3) T cell immunology and CAR T therapy. The shared goals of the ICI Program are to: 1) drive translational immunology research, 2) explore fundamental mechanistic questions in tumor immunology, 3) make ground-breaking discoveries in cancer immunotherapy, and 4) initiate innovative immunotherapy clinical trials to study the underlying basis behind successful anti-tumor responses in humans. Peer-reviewed cancer-related research direct cost support currently totals $3.8M, with NCI funding representing 33% ($1.3M) and total direct costs summing to $4.8M. Ten ICI Program Members currently have a total of 12 CCSG-defined R01-equivalent awards. Using the same definition of cancer-related direct costs in 2014 (i.e., excluding all indirects as well as training and administrative direct costs), peer-reviewed cancer-related research direct costs ($3.8M) are 58% greater compared to 2014 ($2.4M). Since 2015, the ICI Program has 215 cancer-related publications, 21% (45) intra-programmatic, 29% (62) inter-programmatic, 54% (116) with investigators from other institutions, and 17% (32) in high impact journals (i.e., impact factor >8). Compared to 2014, intra-programmatic increased to 21% from 15%, and inter-programmatic has increased, to 29% from 24%. Major future goals include an immune checkpoint inhibitor research initiative to initiate an anti-VISTA clinical trial at NCCC, while continuing to uncover underlying mechanisms of drug efficacy in the laboratory; advancement of cutting-edge immunotherapy/molecular therapeutic combinations in clinical trials at NCCC, while extending collaborations with investigators in the newly created CBT program; a tumor microenvironment initiative to translate cowpea mosaic viral nanoparticle therapy from bench to bedside, in collaboration with the TEC program.; and, in memory T cell and CAR T cell therapy, to advance the engineering of T cells in preclinical work, including initiation of an NKG2D ligand-targeted CAR T cell clinical trial at NCCC.

项目概要/摘要：免疫学和癌症免疫治疗 免疫学和癌症免疫治疗（ICI）计划汇集了21名教师，代表七个 达特茅斯的盖泽尔医学院（盖泽尔），塞耶工程学院和 达特茅斯-希区柯克卫生系统（D-H），与三个中央ICI计划相关的研究兴趣 主题：1）免疫调节和检查点阻断，2）肿瘤微环境，3）T细胞 免疫学和CAR T疗法。ICI计划的共同目标是：1）推动转化免疫学 研究，2）探索肿瘤免疫学的基本机制问题，3）开创性地 癌症免疫疗法的发现，以及4）启动创新的免疫疗法临床试验，以研究 人类成功抗肿瘤反应背后的潜在基础。同行评审的癌症相关研究 直接成本支持目前总计380万美元，其中NCI资金占33%（130万美元）， 总计480万美元。10个ICI计划成员目前共有12个CCSG定义的R 01等效产品 奖使用与2014年相同的癌症相关直接成本定义（即，排除所有间接，以及 培训和行政直接成本），同行评审的癌症相关研究直接成本（380万美元）为58% 与2014年相比（240万美元）。自2015年以来，ICI计划有215篇癌症相关出版物，占21%（45） 方案内，29%（62）方案间，54%（116）与其他机构的调查人员， 17%（32）在高影响力期刊（即，影响因子>8）。与2014年相比， 21%，从15%，和跨方案增加了，从24%到29%。未来的主要目标包括 免疫检查点抑制剂研究计划在NCCC启动抗VISTA临床试验，同时继续 在实验室中揭示药物功效的潜在机制;尖端技术的进步 在NCCC的临床试验中使用免疫疗法/分子治疗组合，同时扩大合作 与新创建的CBT项目的研究人员合作;一个肿瘤微环境倡议， 与TEC计划合作，从实验室到床边的镶嵌病毒纳米颗粒疗法。并在 记忆T细胞和CAR T细胞疗法，以推进临床前工作中的T细胞工程，包括 在NCCC启动NKG 2D配体靶向CAR T细胞临床试验。